Project Grant R01CA272433
Award Date
7/17/24
Completion Date
6/30/29
Dollars Obligated
$1.7M
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
La Jolla, CA 92037, USA
Similar Awards
This Project Grant award from the National Cancer Institute (NCI), under the Cancer Detection and Diagnosis Research program (CFDA 93.394), aims to advance understanding of pancreatic ductal adenocarcinoma (PDAC)-induced cachexia and develop new therapeutic approaches. The $432,889 award to The Johns Hopkins University, with a project period from April 1, 2025 to March 31, 2030, will fund research to: Investigate the effects of downregulating the glutamine transporter SLC1A5 and glutaminase...
This federal Project Grant award from the National Cancer Institute's Cancer Research Manpower program (CFDA 93.398) supports research at the University of North Carolina at Chapel Hill focused on understanding and targeting nutrient scavenging processes in pancreatic ductal adenocarcinoma (PDAC). The $118,912 award, effective from December 1, 2024 to June 30, 2027, will test the hypothesis that upregulation of macropinocytosis can confer resistance to combined autophagy and RAS-pathway...
This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $667,118 to The Regents of the University of California, San Francisco (UCSF) to conduct research aimed at identifying and disabling new pathways for macromolecular recycling in pancreatic cancer. The research focuses on two key lysosomal hydrolases, PLBD1 and LGMN, which are found to be essential for pancreatic ductal adenocarcinoma (PDAC) growth. The project will explore PLBD1's...
This Project Grant award from the National Cancer Institute (CFDA 93.396 Cancer Biology Research) is focused on understanding and overcoming therapeutic resistance in pancreatic ductal adenocarcinoma (PDAC). The $523,480 award to Dana-Farber Cancer Institute (DFCI) will support research to define the role of dysregulated iron metabolism and autophagy in driving resistance to KRAS inhibitor therapies in PDAC. The project aims to develop novel combination therapies that target KRAS inhibitor...
This Project Grant award from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) is funding research at The General Hospital Corporation (Massachusetts General Hospital) to characterize a novel glutathione-related metabolic pathway that drives metastatic progression in pancreatic ductal adenocarcinoma (PDA). The $485,558 award, running from July 1, 2024 through June 30, 2029, will leverage biochemistry, cell biology, genetically-engineered mouse models, and human...
This $125,000 Project Grant award from the National Institute of General Medical Sciences (NIGMS) Biomedical Research and Research Training Program (CFDA 93.859) will support research to investigate the role of cellular metabolism in regulating the formation of precancerous conditions in the pancreas. The key objectives of this 2-year project are to: 1) Determine how the loss of the metabolic enzyme ME1 contributes to the development of acinar-to-ductal metaplasia (ADM) and pancreatic...
The federal Project Grant award R41CA284997 was provided by the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) to Oncotab, Inc., a for-profit organization located in Waxhaw, North Carolina. The $400,000 award, with a project period from June 1, 2025 to May 31, 2026, will support research aimed at developing an optimized radiopharmaceutical to target pancreatic ductal adenocarcinoma (PDAC), a highly lethal form of pancreatic cancer. The project will test...
This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) is focused on investigating the role of the protein Anoctamin 6 (ANO6) in disrupting the transfer of lipids from cancer-associated fibroblasts (CAFs) to pancreatic ductal adenocarcinoma (PDAC) tumor cells through a process called trogocytosis. The $642,755 award, with a project period from March 2025 to February 2030, aims to: Elucidate the signaling mechanisms by which PDAC cells induce...
The National Cancer Institute awarded a $1,960,529 Project Grant (CFDA 93.395 - Cancer Treatment Research) to the University of California, Los Angeles (UCLA) to conduct comprehensive research on adenosine signaling and its impact on the tumor microenvironment in pancreatic ductal adenocarcinoma (PDAC). The 5-year grant, awarded on June 26, 2024, aims to: 1) Evaluate the effects of CD73 inhibition on tumor adenosine metabolism and immunosuppression in a Phase 1/2 clinical trial; 2) Define the...
The National Cancer Institute (NCI) awarded a $166,037 Project Grant (CFDA 93.398 - Cancer Research Manpower) to the University of California, San Diego (UCSD) to conduct research on identifying effective interception strategies for Intraductal Papillary Mucinous Neoplasms (IPMN), a type of pancreatic cyst that may progress to pancreatic ductal adenocarcinoma (PDAC). The research aims to determine the impact of CDK4/6 inhibition on IPMN tumor progression in genetically modified mouse and...